This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1243 entries already.
Final negotiations on proposed EU regulations for plants developed through genetic precision breeding have been delayed, following opposition from a group of MEPs in the European Parliament’s ENVI Committee. The group criticised the European Council and the European Commission for their inflexible stance on issues such as sustainability, labelling, and patent protection.
British targeted gene silencing specialist Laverock Therapeutics Ltd has expanded its seed funding to £20m by a new financing round led by xx and xx. The company said it will use the funds to…l
In a surprise move, Health Commissioner Oliver Várhelyi announced at the Medicines for Europe Annual Conference that the EU Biotech Act will go ahead this year, reversing its provious delay from Q3 2025 to Q3 2026. The legislation has now been fast-tracked because the Commission recognised biotechnology’s rising geostrategic weight.
The UK government has unveiled a new industrial strategy that includes a commitment to invest £380m in engineering biology. The package comprises an initial £196m for research and development, and a further £184m for the expansion and modernisation of pilot and scale-up infrastructure.
Under a new partnership, Plectonic Biotech will use Sonrai’s AI-powered multi-omics platform to speed up development of its Logybody cancer treatment technology. The approach aims to cut side effects and improve precision.
The European Commission has scraped a key piece of Green Deal legislation following political shifts within the European Parliament. The move came after Italy, governed by a far-right administration of Georgia Meloni, aligned itself with the European People’s Party (EPP) on the matter.
British gene and cell therapy manufacturing specialist Cellular Origins Ltd has entered into a collaboration with Johnson & Johnson to develop a scalable, end-to-end automated platform for autologous CAR-T cell manufacturing.
Cultivated meat is expected to reach price parity with conventional meat sooner than previously forecast, according to a new analysis by technology foresight specialist GetFocus.
Lodz-based CDMO Mabion SA has launched a €500,000 oncology services contest at BIO International Convention 2025, aimed at accelerating the development of recombinant protein-based cancer therapies. The contest will culminate at CPHI Worldwide in Frankfurt this October, spotlighting promising biotechs ready to scale their innovation.
AFYREN’s first biorefinery, AFYREN NEOXY, has reached continuous production, marking a key step toward large-scale commercialisation of its bio-based acids. The plant will now ramp up output and fulfill long-term contracts across key sectors like nutrition, cosmetics, and life sciences. European Biotech News talked to CEO Nicolas Sordet about the long and winding road to sucess.